AU2010289794B2 - Determining sensitivity of cells to B-Raf inhibitor treatment by detecting Kras mutation and RTK expression levels - Google Patents
Determining sensitivity of cells to B-Raf inhibitor treatment by detecting Kras mutation and RTK expression levels Download PDFInfo
- Publication number
- AU2010289794B2 AU2010289794B2 AU2010289794A AU2010289794A AU2010289794B2 AU 2010289794 B2 AU2010289794 B2 AU 2010289794B2 AU 2010289794 A AU2010289794 A AU 2010289794A AU 2010289794 A AU2010289794 A AU 2010289794A AU 2010289794 B2 AU2010289794 B2 AU 2010289794B2
- Authority
- AU
- Australia
- Prior art keywords
- ras
- raf
- inhibitor
- mutant
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 140
- 101100381978 Mus musculus Braf gene Proteins 0.000 title claims abstract description 118
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 title claims abstract description 114
- 238000011282 treatment Methods 0.000 title claims abstract description 70
- 102000027426 receptor tyrosine kinases Human genes 0.000 title abstract description 20
- 108091008598 receptor tyrosine kinases Proteins 0.000 title abstract description 20
- 230000014509 gene expression Effects 0.000 title description 26
- 230000035945 sensitivity Effects 0.000 title description 3
- 206010069755 K-ras gene mutation Diseases 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 135
- 230000035772 mutation Effects 0.000 claims abstract description 96
- 238000000034 method Methods 0.000 claims abstract description 94
- 101710113436 GTPase KRas Proteins 0.000 claims description 124
- DEZZLWQELQORIU-RELWKKBWSA-N GDC-0879 Chemical group N=1N(CCO)C=C(C=2C=C3CCC(/C3=CC=2)=N\O)C=1C1=CC=NC=C1 DEZZLWQELQORIU-RELWKKBWSA-N 0.000 claims description 25
- 102200006539 rs121913529 Human genes 0.000 claims description 13
- 206010009944 Colon cancer Diseases 0.000 claims description 12
- 210000004072 lung Anatomy 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 229940102297 B-raf kinase inhibitor Drugs 0.000 claims description 3
- 239000002774 b raf kinase inhibitor Substances 0.000 claims description 3
- 238000012163 sequencing technique Methods 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 abstract description 21
- 108700042226 ras Genes Proteins 0.000 abstract description 20
- 239000003446 ligand Substances 0.000 abstract description 18
- 102000004169 proteins and genes Human genes 0.000 abstract description 13
- 230000002018 overexpression Effects 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 69
- 102000001301 EGF receptor Human genes 0.000 description 54
- 108060006698 EGF receptor Proteins 0.000 description 54
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 54
- 102000016914 ras Proteins Human genes 0.000 description 46
- 239000000523 sample Substances 0.000 description 44
- 201000011510 cancer Diseases 0.000 description 37
- 108091033319 polynucleotide Proteins 0.000 description 34
- 102000040430 polynucleotide Human genes 0.000 description 34
- 239000002157 polynucleotide Substances 0.000 description 34
- 102200055464 rs113488022 Human genes 0.000 description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 31
- 108090000765 processed proteins & peptides Proteins 0.000 description 31
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 31
- 101800003838 Epidermal growth factor Proteins 0.000 description 30
- 229940116977 epidermal growth factor Drugs 0.000 description 30
- 229920001184 polypeptide Polymers 0.000 description 30
- 102000004196 processed proteins & peptides Human genes 0.000 description 30
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 27
- 108010014186 ras Proteins Proteins 0.000 description 27
- 230000011664 signaling Effects 0.000 description 25
- 201000010099 disease Diseases 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 description 18
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 description 18
- 230000006698 induction Effects 0.000 description 18
- 230000004913 activation Effects 0.000 description 17
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 17
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 16
- 229940120982 tarceva Drugs 0.000 description 15
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 14
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 14
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 13
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 12
- 238000002493 microarray Methods 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 11
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 11
- 230000037361 pathway Effects 0.000 description 11
- 102000001708 Protein Isoforms Human genes 0.000 description 10
- 108010029485 Protein Isoforms Proteins 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 230000019491 signal transduction Effects 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- 239000012824 ERK inhibitor Substances 0.000 description 9
- 230000001413 cellular effect Effects 0.000 description 9
- 210000001072 colon Anatomy 0.000 description 9
- 201000002528 pancreatic cancer Diseases 0.000 description 9
- 230000004043 responsiveness Effects 0.000 description 9
- 102100039788 GTPase NRas Human genes 0.000 description 8
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 8
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 description 8
- 201000001441 melanoma Diseases 0.000 description 8
- 230000036515 potency Effects 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 7
- YZDJQTHVDDOVHR-UHFFFAOYSA-N PLX-4720 Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(Cl)=CN=C3NC=2)=C1F YZDJQTHVDDOVHR-UHFFFAOYSA-N 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 102200006541 rs121913530 Human genes 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 231100000504 carcinogenesis Toxicity 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000012775 microarray technology Methods 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 231100000590 oncogenic Toxicity 0.000 description 6
- 230000002246 oncogenic effect Effects 0.000 description 6
- 102200006532 rs112445441 Human genes 0.000 description 6
- 102200006531 rs121913529 Human genes 0.000 description 6
- 102200006537 rs121913529 Human genes 0.000 description 6
- 102200006538 rs121913530 Human genes 0.000 description 6
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 5
- 208000005623 Carcinogenesis Diseases 0.000 description 5
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 5
- 101100193693 Kirsten murine sarcoma virus K-RAS gene Proteins 0.000 description 5
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 5
- 230000036952 cancer formation Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- -1 phospho Chemical class 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 102220197833 rs112445441 Human genes 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 108700028369 Alleles Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 102000009465 Growth Factor Receptors Human genes 0.000 description 4
- 108010009202 Growth Factor Receptors Proteins 0.000 description 4
- 229940124647 MEK inhibitor Drugs 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- 230000001594 aberrant effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 230000006552 constitutive activation Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 229940121647 egfr inhibitor Drugs 0.000 description 4
- 208000037841 lung tumor Diseases 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- ZGBGPEDJXCYQPH-UHFFFAOYSA-N 3-(2-cyanopropan-2-yl)-N-[4-methyl-3-[(3-methyl-4-oxo-6-quinazolinyl)amino]phenyl]benzamide Chemical compound C1=C(NC=2C=C3C(=O)N(C)C=NC3=CC=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(C)(C)C#N)=C1 ZGBGPEDJXCYQPH-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 238000011319 anticancer therapy Methods 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000000869 mutational effect Effects 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 229960003787 sorafenib Drugs 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 102100038778 Amphiregulin Human genes 0.000 description 2
- 108010033760 Amphiregulin Proteins 0.000 description 2
- 101800001382 Betacellulin Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 101150039808 Egfr gene Proteins 0.000 description 2
- 102100030323 Epigen Human genes 0.000 description 2
- 108010016906 Epigen Proteins 0.000 description 2
- 101800000155 Epiregulin Proteins 0.000 description 2
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 2
- 108091006109 GTPases Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 2
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000014413 Neuregulin Human genes 0.000 description 2
- 108050003475 Neuregulin Proteins 0.000 description 2
- 102400000058 Neuregulin-1 Human genes 0.000 description 2
- 108090000556 Neuregulin-1 Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- OYONTEXKYJZFHA-SSHUPFPWSA-N PHA-665752 Chemical compound CC=1C(C(=O)N2[C@H](CCC2)CN2CCCC2)=C(C)NC=1\C=C(C1=C2)/C(=O)NC1=CC=C2S(=O)(=O)CC1=C(Cl)C=CC=C1Cl OYONTEXKYJZFHA-SSHUPFPWSA-N 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102100029837 Probetacellulin Human genes 0.000 description 2
- 102100025498 Proepiregulin Human genes 0.000 description 2
- 229940123690 Raf kinase inhibitor Drugs 0.000 description 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 2
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 2
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000007783 downstream signaling Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229940080607 nexavar Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 102000051624 phosphatidylethanolamine binding protein Human genes 0.000 description 2
- 108700021017 phosphatidylethanolamine binding protein Proteins 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 208000017572 squamous cell neoplasm Diseases 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 235000002374 tyrosine Nutrition 0.000 description 2
- 150000003668 tyrosines Chemical class 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- YABJJWZLRMPFSI-UHFFFAOYSA-N 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine Chemical compound N=1C2=CC(OC=3C=C(N=CC=3)C=3NC(=CN=3)C(F)(F)F)=CC=C2N(C)C=1NC1=CC=C(C(F)(F)F)C=C1 YABJJWZLRMPFSI-UHFFFAOYSA-N 0.000 description 1
- FPYJSJDOHRDAMT-KQWNVCNZSA-N 1h-indole-5-sulfonamide, n-(3-chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1h-pyrrol-2-yl]methylene]-2,3-dihydro-n-methyl-2-oxo-, (3z)- Chemical compound C=1C=C2NC(=O)\C(=C/C3=C(C(C(=O)N4CCN(C)CC4)=C(C)N3)C)C2=CC=1S(=O)(=O)N(C)C1=CC=CC(Cl)=C1 FPYJSJDOHRDAMT-KQWNVCNZSA-N 0.000 description 1
- PFHJLTOLXWXCJH-UHFFFAOYSA-N 2,6-difluoro-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)-3-(propylsulfonylamino)benzamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)NC=2C=C3C(OC)=NNC3=NC=2)=C1F PFHJLTOLXWXCJH-UHFFFAOYSA-N 0.000 description 1
- QFWCYNPOPKQOKV-UHFFFAOYSA-N 2-(2-amino-3-methoxyphenyl)chromen-4-one Chemical compound COC1=CC=CC(C=2OC3=CC=CC=C3C(=O)C=2)=C1N QFWCYNPOPKQOKV-UHFFFAOYSA-N 0.000 description 1
- RWEVIPRMPFNTLO-UHFFFAOYSA-N 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide Chemical compound CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC1=CC=C(I)C=C1F RWEVIPRMPFNTLO-UHFFFAOYSA-N 0.000 description 1
- NBJOUCGADPALIB-UHFFFAOYSA-N 3-(2-aminoethyl)-5-[(4-ethoxyphenyl)methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OCC)=CC=C1C=C1C(=O)N(CCN)C(=O)S1 NBJOUCGADPALIB-UHFFFAOYSA-N 0.000 description 1
- VJNZMSLGVUSPCF-UHFFFAOYSA-N 5-bromo-2-(2-chloro-4-iodoanilino)-n-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C1CC1CONC(=O)C=1C=C(Br)C(F)=C(F)C=1NC1=CC=C(I)C=C1Cl VJNZMSLGVUSPCF-UHFFFAOYSA-N 0.000 description 1
- HEAIZQNMNCHNFD-UHFFFAOYSA-N AMG-208 Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OCC(N1N=2)=NN=C1C=CC=2C1=CC=CC=C1 HEAIZQNMNCHNFD-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- BCBIXNWEWWQJST-UHFFFAOYSA-N ClICl Chemical compound ClICl BCBIXNWEWWQJST-UHFFFAOYSA-N 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- UCEQXRCJXIVODC-PMACEKPBSA-N LSM-1131 Chemical compound C1CCC2=CC=CC3=C2N1C=C3[C@@H]1C(=O)NC(=O)[C@H]1C1=CNC2=CC=CC=C12 UCEQXRCJXIVODC-PMACEKPBSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 230000005723 MEK inhibition Effects 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010071972 N-ras gene mutation Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 101100338491 Oryza sativa subsp. japonica HCT1 gene Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 102000042463 Rho family Human genes 0.000 description 1
- 108091078243 Rho family Proteins 0.000 description 1
- 101100495309 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CDH1 gene Proteins 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 241000838698 Togo Species 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- DVEXZJFMOKTQEZ-JYFOCSDGSA-N U0126 Chemical compound C=1C=CC=C(N)C=1SC(\N)=C(/C#N)\C(\C#N)=C(/N)SC1=CC=CC=C1N DVEXZJFMOKTQEZ-JYFOCSDGSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 201000007538 anal carcinoma Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 description 1
- 229960002271 cobimetinib Drugs 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003020 exocrine pancreas Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 238000013415 human tumor xenograft model Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000010859 live-cell imaging Methods 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229950008001 matuzumab Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- NOFKOGDJJKXTLW-XZOQPEGZSA-N n-[4-[[3-[[(3s,4r)-1-ethyl-3-fluoropiperidin-4-yl]amino]-1h-pyrazolo[3,4-b]pyridin-4-yl]oxy]-3-fluorophenyl]-2-(4-fluorophenyl)-3-oxopyridazine-4-carboxamide Chemical compound F[C@H]1CN(CC)CC[C@H]1NC1=NNC2=NC=CC(OC=3C(=CC(NC(=O)C=4C(N(C=5C=CC(F)=CC=5)N=CC=4)=O)=CC=3)F)=C12 NOFKOGDJJKXTLW-XZOQPEGZSA-N 0.000 description 1
- 230000009125 negative feedback regulation Effects 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000005853 oncogenic activation Effects 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229950006299 pelitinib Drugs 0.000 description 1
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 1
- 208000030940 penile carcinoma Diseases 0.000 description 1
- 201000008174 penis carcinoma Diseases 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000009929 raf Kinases Human genes 0.000 description 1
- 108010077182 raf Kinases Proteins 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102200006540 rs121913530 Human genes 0.000 description 1
- 102220014328 rs121913535 Human genes 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229950005976 tivantinib Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 229950008250 zalutumumab Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014203196A AU2014203196A1 (en) | 2009-08-24 | 2014-06-12 | Determining sensitivity of cells to B-Raf inhibitor treatment by detecting Kras mutation and RTK expression levels |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23646609P | 2009-08-24 | 2009-08-24 | |
| US61/236,466 | 2009-08-24 | ||
| US30114910P | 2010-02-03 | 2010-02-03 | |
| US61/301,149 | 2010-02-03 | ||
| PCT/US2010/046520 WO2011028540A1 (en) | 2009-08-24 | 2010-08-24 | Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014203196A Division AU2014203196A1 (en) | 2009-08-24 | 2014-06-12 | Determining sensitivity of cells to B-Raf inhibitor treatment by detecting Kras mutation and RTK expression levels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2010289794A1 AU2010289794A1 (en) | 2012-04-05 |
| AU2010289794B2 true AU2010289794B2 (en) | 2014-10-02 |
Family
ID=43649583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010289794A Ceased AU2010289794B2 (en) | 2009-08-24 | 2010-08-24 | Determining sensitivity of cells to B-Raf inhibitor treatment by detecting Kras mutation and RTK expression levels |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20120214828A1 (enExample) |
| EP (1) | EP2470898A4 (enExample) |
| JP (1) | JP2013502236A (enExample) |
| KR (1) | KR20120050493A (enExample) |
| CN (1) | CN102859355B (enExample) |
| AU (1) | AU2010289794B2 (enExample) |
| BR (1) | BR112012003926A2 (enExample) |
| CA (1) | CA2771369A1 (enExample) |
| IL (2) | IL218099A0 (enExample) |
| IN (1) | IN2012DN01403A (enExample) |
| MX (1) | MX338856B (enExample) |
| MY (1) | MY165154A (enExample) |
| RU (2) | RU2553379C2 (enExample) |
| SG (2) | SG10201402917XA (enExample) |
| WO (1) | WO2011028540A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0821227A2 (pt) | 2007-12-19 | 2015-06-16 | Cancer Rec Tech Ltd | Composto, composição farmacêutica, método para preparar a mesma, uso de um composto, método para tratar uma doença ou distúrbio, para inibir função de raf e para inibir proliferação celular, inibir progressão do ciclo celular, promover apoptose, ou uma combinação de um ou mais dos mesmos |
| PH12012501361A1 (en) | 2009-12-31 | 2012-10-22 | Centro Nac De Investigaciones Oncologicas Cnio | Tricyclic compounds for use as kinase inhibitors |
| EP2531502B1 (en) | 2010-02-01 | 2014-04-02 | Cancer Research Technology Limited | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
| US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
| US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
| WO2012098387A1 (en) | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors |
| KR20140064971A (ko) * | 2011-09-19 | 2014-05-28 | 제넨테크, 인크. | c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료 |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| WO2013106683A1 (en) * | 2012-01-11 | 2013-07-18 | Duke University | Methods of treating and preventing cancer by disrupting the binding of copper in the map kinase pathway |
| US9216170B2 (en) | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
| HK1211831A1 (zh) * | 2012-08-07 | 2016-06-03 | Novartis Ag | 包含B-RAF抑制剂、EGFR抑制剂和任选PI3Kα抑制剂的药物组合 |
| KR20240146112A (ko) | 2012-08-17 | 2024-10-07 | 에프. 호프만-라 로슈 아게 | 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법 |
| JP2016503399A (ja) * | 2012-10-25 | 2016-02-04 | ノバルティス アーゲー | 組合せ |
| EP2786764B1 (en) | 2013-04-01 | 2017-03-08 | Samsung Electronics Co., Ltd. | Combination therapy using anti-c-met antibody and sorafenib |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| WO2015175705A1 (en) | 2014-05-13 | 2015-11-19 | Board Of Regents, The University Of Texas System | Gene mutations and copy number alterations of egfr, kras and met |
| ES2827024T3 (es) * | 2014-12-23 | 2021-05-19 | Dot Therapeutics 1 Inc | Combinación de inhibidores de Raf y de taxanos |
| WO2017066664A1 (en) * | 2015-10-16 | 2017-04-20 | Millennium Pharmaceuticals, Inc. | Combination therapy including a raf inhibitor for the treatment of colorectal cancer |
| JP6917595B2 (ja) * | 2016-04-28 | 2021-08-11 | デンカ株式会社 | 上皮性細胞成長因子受容体阻害剤に対する癌細胞の耐性を判定する方法 |
| US11471538B2 (en) | 2017-02-10 | 2022-10-18 | INSERM (Institut National de la Santéet de la Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway |
| EP3732285A1 (en) | 2017-12-28 | 2020-11-04 | Tract Pharmaceuticals, Inc. | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
| CA3103983A1 (en) | 2018-06-19 | 2019-12-26 | Biontech Us Inc. | Neoantigens and uses thereof |
| CA3175481A1 (en) * | 2020-04-27 | 2021-11-04 | Verastem, Inc. | Methods of treating abnormal cell growth |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090075267A1 (en) * | 2007-03-13 | 2009-03-19 | Salvatore Siena | K-ras and B-raf mutations and anti-EGFr antibody therapy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2592155B2 (en) * | 2004-06-04 | 2019-09-11 | Genentech, Inc. | EGFR mutations |
| CN101355928B (zh) * | 2005-04-26 | 2013-05-22 | 卫材R&D管理株式会社 | 用于癌症免疫疗法的组合物和方法 |
| WO2007001868A1 (en) * | 2005-06-28 | 2007-01-04 | Genentech, Inc. | Egfr and kras mutations |
| ATE520979T1 (de) * | 2005-08-24 | 2011-09-15 | Bristol Myers Squibb Co | Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors |
-
2010
- 2010-08-24 RU RU2012111231/15A patent/RU2553379C2/ru not_active IP Right Cessation
- 2010-08-24 RU RU2015104058/15A patent/RU2015104058A/ru not_active Application Discontinuation
- 2010-08-24 CA CA2771369A patent/CA2771369A1/en not_active Abandoned
- 2010-08-24 AU AU2010289794A patent/AU2010289794B2/en not_active Ceased
- 2010-08-24 MX MX2012002292A patent/MX338856B/es active IP Right Grant
- 2010-08-24 IN IN1403DEN2012 patent/IN2012DN01403A/en unknown
- 2010-08-24 WO PCT/US2010/046520 patent/WO2011028540A1/en not_active Ceased
- 2010-08-24 EP EP10814253A patent/EP2470898A4/en not_active Withdrawn
- 2010-08-24 SG SG10201402917XA patent/SG10201402917XA/en unknown
- 2010-08-24 BR BR112012003926-1A patent/BR112012003926A2/pt not_active Application Discontinuation
- 2010-08-24 JP JP2012526924A patent/JP2013502236A/ja active Pending
- 2010-08-24 MY MYPI2012000821A patent/MY165154A/en unknown
- 2010-08-24 CN CN201080048007.0A patent/CN102859355B/zh not_active Expired - Fee Related
- 2010-08-24 SG SG2012012860A patent/SG178866A1/en unknown
- 2010-08-24 US US13/392,405 patent/US20120214828A1/en not_active Abandoned
- 2010-08-24 KR KR1020127007529A patent/KR20120050493A/ko not_active Ceased
-
2012
- 2012-02-14 IL IL218099A patent/IL218099A0/en unknown
-
2014
- 2014-05-21 US US14/284,027 patent/US20150164895A1/en not_active Abandoned
- 2014-10-30 IL IL235398A patent/IL235398A0/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090075267A1 (en) * | 2007-03-13 | 2009-03-19 | Salvatore Siena | K-ras and B-raf mutations and anti-EGFr antibody therapy |
Non-Patent Citations (1)
| Title |
|---|
| TAKEZAWA, K. et al, Cancer Research, July 2009, Vol. 69, pages 6515-6521 * |
Also Published As
| Publication number | Publication date |
|---|---|
| IL218099A0 (en) | 2012-04-30 |
| BR112012003926A2 (pt) | 2020-08-11 |
| MY165154A (en) | 2018-02-28 |
| EP2470898A1 (en) | 2012-07-04 |
| HK1175248A1 (zh) | 2013-06-28 |
| KR20120050493A (ko) | 2012-05-18 |
| CN102859355A (zh) | 2013-01-02 |
| AU2010289794A1 (en) | 2012-04-05 |
| MX2012002292A (es) | 2012-03-19 |
| SG10201402917XA (en) | 2014-08-28 |
| MX338856B (es) | 2016-05-03 |
| WO2011028540A1 (en) | 2011-03-10 |
| CN102859355B (zh) | 2015-10-07 |
| RU2012111231A (ru) | 2013-10-10 |
| CA2771369A1 (en) | 2011-03-10 |
| IL235398A0 (en) | 2014-12-31 |
| RU2015104058A (ru) | 2015-06-10 |
| JP2013502236A (ja) | 2013-01-24 |
| IN2012DN01403A (enExample) | 2015-06-05 |
| EP2470898A4 (en) | 2013-03-13 |
| US20150164895A1 (en) | 2015-06-18 |
| US20120214828A1 (en) | 2012-08-23 |
| RU2553379C2 (ru) | 2015-06-10 |
| SG178866A1 (en) | 2012-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010289794B2 (en) | Determining sensitivity of cells to B-Raf inhibitor treatment by detecting Kras mutation and RTK expression levels | |
| Guo et al. | MET-dependent solid tumours—molecular diagnosis and targeted therapy | |
| Sheu et al. | Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma | |
| Shigematsu et al. | Somatic mutations of the HER2 kinase domain in lung adenocarcinomas | |
| Regales et al. | Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer | |
| Wynes et al. | FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies | |
| Mossé et al. | Inhibition of ALK signaling for cancer therapy | |
| Gazdar | Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy | |
| Hack et al. | HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development | |
| Giubellino et al. | Targeting the Met signaling pathway in renal cancer | |
| US20130230511A1 (en) | Biomarkers for response to tyrosine kinase pathway inhibitors in cancer | |
| Cheng et al. | The landscape of EGFR pathways and personalized management of non-small-cell lung cancer | |
| Wen et al. | Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma | |
| JP6149034B2 (ja) | 上皮成長因子受容体遺伝子における変異 | |
| de Castro et al. | β-catenin expression pattern in primary oesophageal squamous cell carcinoma. Relationship with clinicopathologic features and clinical outcome | |
| Brijwani et al. | Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2 | |
| Szkandera et al. | A functional germline variant in GLI1 implicates hedgehog signaling in clinical outcome of stage II and III colon carcinoma patients | |
| Xu et al. | EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib | |
| Dias-Santagata et al. | A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas | |
| AU2014203196A1 (en) | Determining sensitivity of cells to B-Raf inhibitor treatment by detecting Kras mutation and RTK expression levels | |
| HK1175248B (en) | Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels | |
| Goetsch et al. | Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers | |
| US20110269139A1 (en) | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators | |
| Semadhi et al. | Lung cancer: Biomarkers, tyrosine kinase inhibitors and monoclonal antibodies | |
| Chitale | Lung and Mediastinal Tumors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |